ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company focused on developing treatments for eye diseases, has announced the progression of its lead drug candidate, CLS-AX, into Phase 3 clinical development for wet age-related macular degeneration (wet AMD (NASDAQ:AMD)). The decision follows positive topline results from the Phase 2b ODYSSEY trial, which were presented at the recent Annual Meeting of the American Academy of Ophthalmology.
CLS-AX is designed to be administered via Clearside's proprietary SCS Microinjector® for suprachoroidal injection, potentially offering a longer-acting treatment for retinal diseases. During the ODYSSEY trial, CLS-AX showed an 84% reduction in injection frequency after the initial dose and extended treatment intervals, with a significant number of participants not requiring additional treatment for up to six months.
The company's Chief Medical Officer, Victor Chong, M.D., MBA, expressed that the ODYSSEY trial supports the potential of CLS-AX to maintain visual acuity with fewer injections and office visits, which could benefit patients, caregivers, and payors. He also noted the well-tolerated safety profile of the drug.
The SCS Microinjector® has been highlighted for its versatility in delivering a range of drug candidates directly to the back of the eye, aiming to improve efficacy and reduce toxic effects on non-diseased cells. The recent trial data aligns with outcomes from the use of Clearside's FDA-approved XIPERE® for uveitic macular edema, which also demonstrated sustained effects after a single dose.
Wet AMD is a leading cause of legal blindness in individuals over age 55 in the United States, with approximately 11 million patients affected by AMD, of which about 10% have the wet form. Current treatments typically involve frequent injections, which can be burdensome for patients and may lead to reduced compliance.
The announcement of advancing CLS-AX into Phase 3 development marks a significant milestone for Clearside Biomedical and the potential treatment landscape for wet AMD. The information is based on a press release statement from Clearside Biomedical, Inc.
In other recent news, Clearside Biomedical announced the successful completion of its Phase 2b ODYSSEY clinical trial for CLS-AX, a treatment for wet age-related macular degeneration. Results showed that 67% of participants did not require additional treatment for up to 6 months, which could potentially reduce treatment frequency by 84%. Moreover, Clearside reported a net loss of $11.8 million for Q1 2024, with operating expenses at $8 million, less than the estimated $10 million. The company ended the quarter with $35 million in cash, providing financial stability into Q3 2025.
Analysts from H.C. Wainwright, Jones Trading, and Chardan Capital Markets have maintained a positive outlook on Clearside Biomedical, with price targets ranging from $5 to $6. The company also recently welcomed Glenn C. Yiu, M.D., Ph.D., to its Scientific Advisory Board and elected three directors at its annual meeting. These recent developments highlight Clearside Biomedical's ongoing efforts in its operations and leadership.
Finally, Clearside Biomedical is preparing for a Phase 3 program and plans to share further data at upcoming medical meetings. These updates are the latest in a series of recent developments for the company.
InvestingPro Insights
As Clearside Biomedical (NASDAQ:CLSD) advances its lead drug candidate CLS-AX into Phase 3 clinical development, investors are taking note of the company's potential in the eye disease treatment market. According to InvestingPro data, CLSD has seen a significant return of 61.37% over the last year, reflecting growing investor confidence in the company's pipeline and technology.
The company's focus on developing innovative treatments for eye diseases aligns with its impressive revenue growth. InvestingPro data shows that Clearside's revenue growth stands at a remarkable 365.02% for the last twelve months as of Q2 2024. This substantial increase could be attributed to the company's progress with CLS-AX and the success of its proprietary SCS Microinjector® technology.
However, it's important to note that Clearside is still in a growth phase and faces financial challenges typical of biopharmaceutical companies in development stages. An InvestingPro Tip indicates that the company is "quickly burning through cash," which is not uncommon for firms investing heavily in clinical trials and research. Additionally, another InvestingPro Tip suggests that analysts do not anticipate the company will be profitable this year, reflecting the ongoing investment required for drug development.
Despite these challenges, there are positive signals. An InvestingPro Tip reveals that three analysts have revised their earnings upwards for the upcoming period, possibly in response to the promising Phase 2b ODYSSEY trial results for CLS-AX. This upward revision could indicate growing optimism about the company's near-term prospects.
For investors interested in a deeper analysis, InvestingPro offers 11 additional tips for Clearside Biomedical, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.